In order to confirm the efficacy of @entity619 ( @entity3784 ) incorporated into liposomes ( @entity3784 -liposomes) on @entity731 , drug delivery to @entity731 and the antiatherosclerotic effect by @entity3784 -liposomes were investigated in atherogenic @entity19 . @entity3784 -liposomes were prepared with egg yolk @entity2434 , @entity165 and @entity17521 in a lipid molar ratio of 7/2/1 by the hydration method and then adjusted to three different particle sizes to clarify the influence of particle size on the drug delivery to @entity731 and the effect on @entity731 . The particle sizes of @entity3784 -liposomes were 519 nm (L500), 202 nm (L200) and 68.6 nm (L70), respectively. In both size, @entity3784 concentration and @entity3784 /lipid molar ratio in @entity3784 -liposomes suspension were 1 mg @entity3784 /ml and 0.134 mol @entity3784 /mol total lipids, respectively. Atherogenic @entity19 used as an experimental model develop an @entity731 in the aorta and they were prepared by feeding an atherogenic diet for 14 weeks. The aortic pharmacokinetics of @entity3784 -liposomes was examined by intravenous administration to atherogenic @entity19 . The aortic uptake clearance of @entity3784 in atherogenic @entity19 treated with L200 was 2.6--3.2 fold greater than that in animals treated with L500, L70 or free @entity3784 (f- @entity3784 ). Furthermore, the effects of @entity3784 -liposomes on @entity731 were examined by intravenous administration to atherogenic @entity19 once a week from 8 to 14 weeks. The antiatherosclerotic effects of @entity3784 -liposomes were evaluated by determination of the aortic @entity14839 (CE) level. The aortic CE level in atherogenic @entity19 treated with L200 (55 microg @entity3784 /kg) was significantly lower than that in animals treated with PBS. The antiatherosclerotic effect of L200 (55 microg @entity3784 /kg) was significantly more potent than that of f- @entity3784 (550 microg @entity3784 /kg). These findings suggest that efficient delivery of @entity3784 to the @entity731 by L200 induces an excellent antiatherosclerotic effect at a lower dose. Therefore, L200 may be useful in the development of drug delivery systems for @entity731 therapy.

Efficient drug delivery to @entity731 and the antiatherosclerotic effect by @entity619 incorporated into liposomes in atherogenic XXXX .

@entity17521 :: ('MESH:C002290', 'Chemical') :: ['dicetylphosphate'] @entity14839 :: ('CHEBI:17002', 'Chemical') :: ['cholesterol ester'] @entity3784 :: ('CHEBI:4470', 'Chemical') :: ['DXM'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis', 'atherosclerotic lesion', 'atherosclerotic lesions'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity19 :: (10090,Species) :: ['mice']
